Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique Spaëth

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|June 17, 2006
[Recent advances on the use of erythropoietin in oncology]Dominique Spaëth
Expert Review of Anticancer Therapy|June 7, 2008
Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemiaDominique Spaëth
La Revue Du Praticien|February 6, 2007
[Chemotherapy-induced alopecia]Dominique Spaëth, Nathalie Rosso, Laetitia Clivot
Therapie|November 20, 2013
Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetronDiane Pivot, Lucie Javot, Dominique Swiegot, et al.
Therapie|May 26, 2009
[Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors]Stéphane Oudard, Elisabeth Quoix, Arash Jenabian, et al.
Oncology|June 13, 2008
Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapyDominique Spaëth, Bernard Desablens, Philippe Rodon, et al.
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyThomas Bachelot, Céline Bourgier, Claire Cropet, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
Plos One|September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|June 17, 2006
[Recent advances on the use of erythropoietin in oncology]Dominique Spaëth
Expert Review of Anticancer Therapy|June 7, 2008
Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemiaDominique Spaëth
La Revue Du Praticien|February 6, 2007
[Chemotherapy-induced alopecia]Dominique Spaëth, Nathalie Rosso, Laetitia Clivot
Therapie|November 20, 2013
Two cases of recurrent priapism during antineoplastic chemotherapy: think about ondansetronDiane Pivot, Lucie Javot, Dominique Swiegot, et al.
Therapie|May 26, 2009
[Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors]Stéphane Oudard, Elisabeth Quoix, Arash Jenabian, et al.
Oncology|June 13, 2008
Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapyDominique Spaëth, Bernard Desablens, Philippe Rodon, et al.
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyThomas Bachelot, Céline Bourgier, Claire Cropet, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
Plos One|September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
Pageof 2